Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 2/2013

01-02-2013 | Original article

Diffusion-weighted MRI in locally advanced rectal cancer

Pathological response prediction after neo-adjuvant radiochemotherapy

Authors: M. Intven, MD, O. Reerink, MD, PhD, M.E.P. Philippens, MD, PhD

Published in: Strahlentherapie und Onkologie | Issue 2/2013

Login to get access

Abstract

Background and purpose

The aim of this study was to assess the predictive potential of diffusion-weighted magnetic resonance imaging (MRI) for the selection of favorable pathological responders after radiochemotherapy for locally advanced rectal cancer.

Patients and methods

In 59 patients with locally advanced rectal cancer, the apparent diffusion coefficient (ADC) in the tumor was obtained at 3 Tesla before radiochemotherapy and surgery. The predictive potential for pathological complete response (pCR) and good response (GR) was assessed. GR was defined as pCR and near-pCR based on the tumor regression grade.

Results

The GR group consisted of 13 patients (22%) with 9 complete responders. Both the preradiochemotherapy ADC values and relative change in ADC (ΔADC) were predictive for pathological response. Preradiochemotherapy ADC values showed a positive predictive value of 42% for pCR and 67% for GR using a similar cut-off value of 0.97*10−3 mm2/s. For ΔADC, the optimal threshold for predicting GR or pCR was a 41% increase of the ADC. With this threshold, positive predictive values of 64% and 91% were found for pCR and GR, respectively.

Conclusion

Low preradiochemotherapy ADC values and high ΔADC correspond to pathological good response. Diffusion-weighted MRI may be used as an additional tool for selecting good treatment responders after radiochemotherapy.
Literature
1.
Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 358:1291–1304CrossRef
2.
MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal cancer. Lancet 341:457–460PubMedCrossRef
3.
Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef
4.
Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123PubMedCrossRef
5.
Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRef
6.
Maas M, Nelemans PJ, Valentini V et al (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11:835–844PubMedCrossRef
7.
Rodel C, Martus P, Papadoupolos T et al (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696PubMedCrossRef
8.
Eich HT, Stepien A, Zimmermann C et al (2011) Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer: prognostic significance of tumor regression. Strahlenther Onkol 187:225–230PubMedCrossRef
9.
Habr-Gama A, Perez RO (2009) Non-operative management of rectal cancer after neoadjuvant chemoradiation. Br J Surg 96:125–127PubMedCrossRef
10.
O’Neill BD, Brown G, Heald RJ et al (2007) Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 8:625–633CrossRef
11.
Bujko K, Kepka L, Nowacki MP (2007) Chemoradiotherapy alone for rectal cancer: a word of caution. Lancet Oncol 8:860–862PubMedCrossRef
12.
Habr-Gama A, Perez RO, Nadalin W et al (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240:711–718PubMed
13.
Bujko K, Richter P, Kolodziejczyk M et al (2009) Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders. Radiother Oncol 92:195–201PubMedCrossRef
14.
Janssen MH, Ollers MC, Riedl RG et al (2010) Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys 77:392–399PubMedCrossRef
15.
Hamstra DA, Rehemtulla A, Ross BD (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104–4109PubMedCrossRef
16.
Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125PubMed
17.
Kwee TC, Takahara T, Ochiai R et al (2008) Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol 18:1937–1952PubMedCrossRef
18.
Hussain SM, Outwater EK, Siegelman ES (1999) Mucinous versus nonmucinous rectal carcinomas: differentiation with MR imaging. Radiology 213:79–85PubMed
19.
Kim MJ, Park JS, Park SI et al (2003) Accuracy in differentiation of mucinous and nonmucinous rectal carcinoma on MR imaging. J Comput Assist Tomogr 27:48–55PubMedCrossRef
20.
Valentini V, Aristei C, Glimelius B et al (2009) Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 92:148–163PubMedCrossRef
21.
Roels S, Duthoy W, Haustermans K et al (2006) Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys 65:1129–1142PubMedCrossRef
22.
Bol GH, Kotte AN, Heide UA van der, Lagendijk JJ (2009) Simultaneous multi-modality ROI delineation in clinical practice. Comput Methods Programs Biomed 96:133–140PubMedCrossRef
23.
24.
Mandard AM, Dalibard F, Mandard JC et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73:2680–2686PubMedCrossRef
25.
Kim SH, Lee JY, Lee JM et al (2010) Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer. Eur Radiol 21(5):987–995PubMedCrossRef
26.
Lambrecht M, Vandecaveye V, De Keyzer F et al (2012) Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. Int J Radiat Oncol Biol Phys 82(2):863–870PubMedCrossRef
27.
Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622–1635PubMedCrossRef
28.
Dzik-Jurasz A, Domenig C, George M et al (2002) Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360:307–308PubMedCrossRef
29.
Barbaro B, Vitale R, Valentini V et al (2012) Diffusion-weighted magnetic resonance imaging in monitoring rectal cancer response to neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 83:594–599PubMed
30.
Ippolito D, Monguzzi L, Guerra L et al (2012) Response to neoadjuvant therapy in locally advanced rectal cancer: assessment with diffusion-weighted MR imaging and 18FDG PET/CT. Abdom Imaging (Epub ahead of print)
31.
Kim SH, Lee JM, Hong SH et al (2009) Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 253:116–125PubMedCrossRef
32.
Glynne-Jones R, Anyemene N (2009) Histologic response grading after chemoradiation in locally advanced rectal cancer: a proposal for standardized reporting. Int J Radiat Oncol Biol Phys 73:971–973PubMedCrossRef
33.
Habr-Gama A, Perez RO, Proscurshim I et al (2008) Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys 71:1181–1188PubMedCrossRef
34.
Veenhof AA, Bloemena E, Engel AF et al (2009) The relationship of histological tumor regression grade (TRG) and two different time intervals to surgery following radiation therapy for locally advanced rectal cancer. Int J Colorectal Dis 24:1091–1096PubMedCrossRef
35.
Lambregts DM, Beets GL, Maas M et al (2011) Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability. Eur Radiol 21:2567–2574PubMedCrossRef
36.
Habr-Gama A, Perez RO, Proscurshim I et al (2006) Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 10:1319–1328PubMedCrossRef
37.
Maas M, Beets-Tan RG, Lambregts DM et al (2011) Wait-and-See policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29:4633–4640PubMedCrossRef
38.
Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J (2008) Complete clinical response after preoperative chemoradiation in rectal cancer: is a “wait and see” policy justified? Dis Colon Rectum 51:10–19PubMedCrossRef
Metadata
Title
Diffusion-weighted MRI in locally advanced rectal cancer
Pathological response prediction after neo-adjuvant radiochemotherapy
Authors
M. Intven, MD
O. Reerink, MD, PhD
M.E.P. Philippens, MD, PhD
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Strahlentherapie und Onkologie / Issue 2/2013
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-012-0270-5

Other articles of this Issue 2/2013

Strahlentherapie und Onkologie 2/2013 Go to the issue

Abstracts

Abstracts der 29. Jahrestagung der Österreichischen Gesellschaft für Radioonkologie, Radiobiologie und Medizinische Radiophysik (ÖGRO 2012)

Erratum

Erratum to: Radiotherapy in stage I-III follicular non-Hodgkin lymphoma. Retrospective analysis of a series of 50 patients

Original article

Radiotherapy for achillodynia

Original article

Endocrine and visual function after fractionated stereotactic radiotherapy of perioptic tumors

Literatur kommentiert

Resektion plus adjuvante Chemotherapie verbessert Überleben beim fortgeschrittenen Pankreaskarzinom

Original article

Hypoxia-related molecules HIF-1α, CA9, and osteopontin